Apr 29, 2020
UCB's Cimzia is Making Inroads in the Treatment of Axial Disease, with Significant Uptake in Non-Radiographic Axial Spondyloarthritis and a Positive Treatment Halo in Ankylosing Spondylitis
Feb 20, 2020
UCB Full Year Report 2019
Jan 15, 2020
CIMZIA® (certolizumab pegol) Now Approved in Canada for the Treatment of Non-Radiographic Axial Spondyloarthritis
Dec 16, 2019
Promising Early Launch Metrics for AbbVie's Rinvoq (upadacitinib) to Help JAK Inhibitors Solidify Their Position as Second-Line Leaders in Rheumatoid Arthritis, According to Spherix Global Insights
Jul 25, 2019
UCB Half Year Report 2019: UCB's Strong Performance Enables Continued Investment Into Future Growth Drivers
Mar 28, 2019
CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
Mar 28, 2019
FDA approves treatment for patients with a type of inflammatory arthritis
Mar 11, 2019
Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)
Mar 01, 2019
New Data Affirms Strength of UCB Immuno-Dermatology Portfolio
Feb 28, 2019
UCB Full Year Report 2018: 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB's Strong Pipeline
Oct 30, 2018
UCB First Nine Months Interim Report 2018: UCB tracking well towards full year financial outlook
May 29, 2018
UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
May 16, 2018
CIMZIA® (certolizumab pegol) is the First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study
Mar 22, 2018
CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.
Mar 05, 2018
Global Psoriasis Pipeline Drugs Market 2018-2023: Cimzia (Certolizumab Pegol), Tildrakizumab (MK-3222), Risankizumab (BI 655066), FP187, Skilarence (LAS41008) & Duobrii (IDB 118)
Feb 16, 2018
UCB Advances Psoriasis Pipeline with Positive Data at American Academy of Dermatology Annual Meeting (AAD 2018)
Nov 06, 2017
UCB Presents New Findings Advancing Patient Care for Chronic Inflammatory Diseases and Osteoporosis at 2017 ACR/ARHP Annual Meeting